Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• North America dominated the global market, accounting for the largest share of 47% in 2025

  80% confidence

• The market is bifurcating, with innovation focused on severe phenotypes and smart delivery, while policy shifts mandate affordability for mass-market generic access

  80% confidence

• Asthma accounts for 1.4 million emergency department visits and 94,000 hospital inpatient stays annually in the US

  80% confidence

• The direct cost of asthma care is estimated at USD 3,728 per person annually

  80% confidence

• 3,517 asthma deaths were reported in the most recent US data

  80% confidence

• High-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers

  80% confidence

• India reports 34 million asthma cases, creating massive demand for affordable generic inhalers

  80% confidence

• The global smart inhaler market was valued at USD 1.53 billion in 2024 and could reach USD 7.9 billion by 2030

  80% confidence

• China's Volume-Based Procurement (VBP) has slashed generic prices by ~50%, forcing multinationals to abandon legacy generic margins in favor of introducing innovative biologics to the self-pay and private insurance tiers

  80% confidence

• The FDA approved 50 novel drugs in 2024

  80% confidence

• The global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a CAGR of 4.50% during the forecast period 2026–2035

  80% confidence

• There are 4.7 million children with asthma in the US, contributing to a total affected population of 24.9 million

  80% confidence

Cited in these Via News reports

• GSK's Six-Monthly Asthma Biologic Could Reshape Treatment Standards From London to Lagos →
• Gene Therapy, mRNA and CRISPR: The Global Biotech Boom Reshaping How the World Finances Medicine →